SCHEMBL4487984

SCHEMBL4487984

O=C(c1ccc(O)cc1)N(C1CC1)C1CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 1/20 0.54
ALOX15 P16050 1/20 0.54
ALOX12 P18054 1/20 0.54
RECQL P46063 1/20 0.54
ADAM17 P78536 1/20 0.54
HSD11B1 P28845 10/20 0.49
CHRM4 P08173 1/20 0.47
MAPT P10636 2/20 0.44
HTT P42858 2/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
PKM P14618 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
SLC6A4 P31645 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4486860 0.90 MEN1 (0.68) LMNAMEN1KMT2AKDM4EALOX15
SCHEMBL8361113 0.81 LMNA (0.77) LMNAMEN1KMT2AKDM4EALOX15
SCHEMBL4596398 0.75 LMNA (0.68) LMNAMEN1KMT2AKDM4EALOX15
SCHEMBL9584980 0.75 MEN1 (0.68) LMNAMEN1KMT2AKDM4EALOX15
SCHEMBL8361111 0.75 LMNA (0.68) LMNAMEN1KMT2AKDM4EALOX15
SCHEMBL9540808 0.75 LMNA (0.63) LMNAMEN1KMT2AKDM4EALOX15
SCHEMBL29051501 0.75 LMNA (0.63) LMNAMEN1KMT2AKDM4EALOX15
SCHEMBL4486060 0.73 HSD11B1 (0.61) LMNAMEN1KMT2AHSD11B1OPRM1
SCHEMBL9542146 0.73 LMNA (0.66) LMNAMEN1KMT2AKDM4EALOX15
SCHEMBL812387 0.73 LMNA (0.66) LMNAMEN1KMT2AKDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576120-B2 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-08-18 US disclosed
EP-1720544-B1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2008-03-19 EP disclosed
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. LES LABORATORATIES SERVIER (FR) 2007-08-23 US disclosed
EP-1720544-A1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier (FR) 2006-11-15 EP disclosed
WO-2005089747-A1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. HRH2, HNMT, HRH1 LMNA 2552/4885MEN1 998/4885KMT2A 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.